A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group

2012 ◽  
Vol 48 (4) ◽  
pp. 579-585 ◽  
Author(s):  
Sylvain Baruchel ◽  
Alberto Pappo ◽  
Mark Krailo ◽  
K. Scott Baker ◽  
Bing Wu ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Ewing Sarcoma ◽  
Soft Tissue Sarcomas ◽  
Phase 2 ◽  
Oncology Group ◽  
Phase 2 Trial

scholarly journals A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas

Cancer ◽  
2019 ◽  
Vol 125 (14) ◽  
pp. 2445-2454 ◽  
Author(s):  
Robin L. Jones ◽  
Sant P. Chawla ◽  
Steven Attia ◽  
Patrick Schöffski ◽  
Hans Gelderblom ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase 1 ◽  
Soft Tissue Sarcomas ◽  
Phase 2 ◽  
Safety And Efficacy ◽  
Randomized Controlled ◽  
Phase 2 Trial

A phase 2 trial of 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and non-resectable soft tissue sarcomas.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 11019-11019 ◽  
Author(s):  
Brian Andrew Van Tine ◽  
Mark Agulnik ◽  
Richard D. Olson ◽  
Gerald M. Walsh ◽  
Arthur Klausner ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Phase 2 ◽  
Phase 2 Trial

Neoadjuvant Hypofractionated Radiotherapy and Chemotherapy for Extremity Soft Tissue Sarcomas: Safety, Feasibility, and Early Oncologic Outcomes of a Phase 2 Trial

2021 ◽  
Author(s):  
Maria Leticia Gobo Silva ◽  
Celso Abdon Lopes de Mello ◽  
Samuel Aguiar ◽  
Felipe D́Almeida Costa ◽  
Paulo Roberto Stevanato Filho ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Oncologic Outcomes ◽  
Hypofractionated Radiotherapy ◽  
Phase 2 ◽  
Phase 2 Trial

scholarly journals Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

Cancer ◽  
2011 ◽  
Vol 118 (3) ◽  
pp. 770-776 ◽  
Author(s):  
Margaret von Mehren ◽  
Cathryn Rankin ◽  
John R. Goldblum ◽  
George D. Demetri ◽  
Vivien Bramwell ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Phase 2 ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Intergroup Trial

scholarly journals Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group

Cancer ◽  
2013 ◽  
Vol 120 (3) ◽  
pp. 344-351 ◽  
Author(s):  
Jubilee Brown ◽  
William E. Brady ◽  
Julian Schink ◽  
Linda Van Le ◽  
Mario Leitao ◽  
...  
Keyword(s):  
Gynecologic Oncology ◽  
Ovarian Tumors ◽  
Gynecologic Oncology Group ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Oncology Group ◽  
Phase 2 Trial

Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).

1987 ◽  
Vol 5 (6) ◽  
pp. 851-861 ◽  
Author(s):  
L H Baker ◽  
J Frank ◽  
G Fine ◽  
S P Balcerzak ◽  
R L Stephens ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Actinomycin D ◽  
Malignant Tumors ◽  
Soft Tissue Sarcomas ◽  
Comparative Trial ◽  
Phase Iii ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Significant Difference

The term soft tissue sarcoma refers to a large variety of malignant tumors arising in extraskeletal connective tissues that connect, support, and surround discrete anatomic structures. All visceral organs also contain a connective stroma that can undergo malignant transformation. Because of the histological similarities of this group of tumors and their relative rarity, treatment prescriptions for patients that have disseminated disease are most often uniform. In this study, we asked the question whether adding a third drug (cyclophosphamide or actinomycin D) to Adriamycin (Adr [Adria Laboratories, Columbus, OH])-(3,3-dimethyl-1-triazeno)- imidazole-4-carboxamide (DTIC) would improve the response rate and/or survival. A unique feature of this cooperative group clinical trial was the mandatory pathology review of the histological material. All patients of the Southwest Oncology Group between June 1, 1976, and November 17, 1979, who had a biopsy-confirmed diagnosis of a soft tissue sarcoma with convincing clinical or biopsy-documented evidence of metastatic disease were eligible for the study. Patients were randomized to receive (1) Adr, 60 mg/m2 intravenously, day 1, and DTIC, 250 mg/m2 every 3 weeks (104 patients); (2) Adr and DTIC as in (1) and cyclophosphamide, 500 mg/m2, day 1 (112 patients); or (3) Adr and DTIC as in (1) and actinomycin D, 1.2 mg/m2, day 1, (119 patients). There was no statistically significant difference in response rates (33%, 34%, and 24%) (P = .25). Median durations of response were 31 weeks in the Adr-DTIC arm, 26 weeks in the cyclophosphamide-DTIC-Adr arm, and 23 weeks in the Adr-DTIC-Actinomycin D arm (P = .78). Median durations of survival were 37, 42, and 50 weeks, respectively. Again, no statistically significant differences were observed (P = .59). Toxicities from each of these treatment arms were formidable and were equivalent. Prognostic factor analysis showed a prognosis based on bone marrow reserve, sex, and pathology subtype favorable to patients.

Sign in / Sign up

Export Citation Format

Share Document